

This document is the preprint version of a published work that appeared in final form in *Am. J. Kidney Dis.*, after peer review and technical editing by the publisher. To access the final edited and published work, see <https://doi.org/10.1053/j.ajkd.2017.09.005>

# American Journal of Kidney Disease

## COL4A5 Founder Mutation Identified in Three Families Leads to an Unusual X-linked Glomerulopathy --Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Article Type:</b>	Case Report
<b>Full Title:</b>	COL4A5 Founder Mutation Identified in Three Families Leads to an Unusual X-linked Glomerulopathy
<b>Order of Authors:</b>	Moumita Barua, M.D. Weili Li Lorenzo Stella Nicole Roslin Saidah Hack Bedra Sharif Ginette Lajoie-Starkell Rohan John Andrew Schwaderer Matthias Wuttke Anna Kottgen Daniel Cattran Andrew Paterson York Pei
<b>Suggested Reviewers:</b>	Jeff Miner
<b>Opposed Reviewers:</b>	

1  
2  
3  
4 *COL4A5* Founder Mutation Identified in Three Families Leads to an Unusual X-linked  
5  
6 Glomerulopathy  
7

8  
9 Moumita Barua MD<sup>1,2,3,4</sup>, Weili Li PhD<sup>5</sup>, Lorenzo Stella PhD<sup>6</sup>, Rohan John MD<sup>7</sup>, Nicole Roslin  
10  
11 PhD<sup>5</sup>, Bedra Sharif PhD<sup>1</sup>, Saidah Hack BSc<sup>1</sup>, Ginette Lajoie-Starkell MD<sup>8</sup>, Andrew L.  
12  
13 Schwaderer MD<sup>9</sup>, Brian Becknell MD PhD<sup>9</sup>, Matthias Wuttke MD<sup>10, 11</sup>, Anna Kottgen MD<sup>10, 11</sup>,  
14  
15 Daniel Cattran MD<sup>1,2,3</sup>, \*Andrew D. Paterson MD<sup>4,5,12</sup>, \*York Pei MD<sup>1,2,3,4</sup>  
16  
17  
18  
19  
20

21 <sup>1</sup>Division of Nephrology, University Health Network, Toronto, Canada  
22

23 <sup>2</sup>Toronto General Research Institute, Toronto General Hospital, Toronto, Canada  
24

25 <sup>3</sup>Department of Medicine, University of Toronto, Canada  
26  
27

28 <sup>4</sup>Institute of Medical Sciences, University of Toronto, Canada  
29

30 <sup>5</sup>Hospital for Sick Children's, Toronto, Canada  
31  
32

33 <sup>6</sup>Department of Chemical Science and Technology, University of Rome Tor Vergata, Rome,  
34  
35 Italy  
36  
37

38 <sup>7</sup>Department of Pathology, University Health Network, Toronto, Canada  
39

40 <sup>8</sup>William Osler Health Center, Toronto, Canada  
41  
42

43 <sup>9</sup>Nephrology Section, Nationwide Children's Hospital Department of Pediatrics, Ohio State  
44  
45 University Center for Clinical and Translational Research, The Research Institute at Nationwide  
46  
47 Children's Hospital  
48  
49

50 <sup>10</sup>Division of Genetic Epidemiology, Institute for Medical Biometry and Statistics, Medical  
51  
52 Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany  
53  
54

55 <sup>11</sup>Division of Nephrology, University of Freiburg, Faculty of Medicine, Freiburg, Germany  
56

57 <sup>12</sup>Epidemiology & Biostatistics, Dalla Lana School of Public Health, University of Toronto  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

\*These authors contributed equally to this work

Correspondence:

Dr. Moumita Barua

200 Elizabeth Street, 8NU-855

Toronto General Hospital

Toronto, ON

M5G 2C4

moumita.barua@uhn.ca

Abstract word count: 179

Manuscript word count: 1494

Running header: *COL4A5* Founder Mutation Leads to Unusual Glomerulopathy

1  
2  
3  
4 Abstract:

5  
6 Alport syndrome (AS) is a rare hereditary disorder caused by mutations in one of three genes  
7  
8 encoding for type IV collagen. Mutations in *COL4A5* on chr.Xq22 cause X-linked AS (XLAS),  
9  
10 which accounts for ~80% of the cases. AS has a variable clinical presentation including  
11  
12 progressive renal failure, hearing loss and ocular defects. Exome sequencing performed in two  
13  
14 affected related males with an undefined X-linked glomerulopathy, characterized by global and  
15  
16 segmental glomerulosclerosis, mesangial hypercellularity and vague basement membrane  
17  
18 immune complex deposition, revealed a *COL4A5* sequence variant, c.T665G, p.Phe222Cys  
19  
20 (NM\_000495, rs281874761), not seen in databases cataloguing natural human genetic variation  
21  
22 including dbSNP138, 1000 Genomes Project release version 01-11-2004, Exome Sequencing  
23  
24 Project 21-06-2014 or ExAC 01-11-2014. Review of the literature identified two additional  
25  
26 families with the same *COL4A5* variant leading to similar atypical histopathological features,  
27  
28 suggesting a unique pathologic mechanism initiated by this specific mutation. Homology  
29  
30 modeling suggests that the substitution will alter the structural and dynamic properties of the  
31  
32 COL4A trimer. Genetic analysis comparing members of the three families indicated a distant  
33  
34 relationship with a shared haplotype implying a founder effect.  
35  
36  
37  
38  
39  
40  
41  
42

43 Index words: *COL4A5* mutations, X-link inheritance, founder mutation, atypical phenotype  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Introduction

5  
6 Alport syndrome (AS) is a rare hereditary disorder, with an estimated prevalence of 1 in 50,000,  
7  
8 caused by mutations in one of three genes coding for Type IV collagen.<sup>1</sup> AS has a variable  
9  
10 clinical presentation including progressive renal failure, hearing loss and ocular defects. It is  
11  
12 characterized by thinning basement membranes and a hallmark degenerative glomerular BM  
13  
14 splitting. Type IV collagen (COL4) is composed of six genetically distinct  $\alpha$ -chains ( $\alpha 1$ - $\alpha 6$ )  
15  
16 arranged in three distinct triplet helical protomers (i.e.  $\alpha 1$ - $\alpha 1$ - $\alpha 2$ ,  $\alpha 3$ - $\alpha 4$ - $\alpha 5$ , and  $\alpha 5$ - $\alpha 5$ - $\alpha 6$ ). In the  
17  
18 kidney, the  $\alpha 5\alpha 5\alpha 6$  network is found in Bowman's capsule.<sup>2</sup>  
19  
20  
21  
22  
23  
24  
25

26 Mutations in *COL4A5* on chrXq22 cause X-linked AS (XLAS) which accounts for ~80% of the  
27  
28 cases, whereas recessive and dominant mutations of *COL4A3* or *COL4A4* on chr2q36-q37 and  
29  
30 chr2q35-37, respectively, account for ~15% and ~5% of the remaining cases.<sup>1</sup> Certain specific  
31  
32 variants of any of the above three genes interfere with the assembly of the  $\alpha 3$ - $\alpha 4$ - $\alpha 5$  (IV)  
33  
34 network in the glomerular BM (GBM) and arrest the normal developmental switch from the  
35  
36 immature  $\alpha 1$ - $\alpha 1$ - $\alpha 2$  (IV) network to the  $\alpha 3$ - $\alpha 4$ - $\alpha 5$  (IV) network.<sup>3, 4</sup> The persistence of an  
37  
38 immature  $\alpha 1$ - $\alpha 1$ - $\alpha 2$  (IV) network is more susceptible to proteolysis and eventually leads to the  
39  
40 "hallmark" degenerative glomerular BM splitting on pathology.  
41  
42  
43  
44  
45  
46  
47

48 We report a family with an X-linked recessive inheritance pattern of renal disease but with  
49  
50 features atypical for any single diagnosis. Genetic analysis reveals a mutation in *COL4A5*,  
51  
52 p.Phe222Cys (NM\_000495, rs281874761), which was previously reported in two families with  
53  
54 similar atypical histopathological characteristics.<sup>5, 6</sup> Homology modeling predicts that the  
55  
56 substitution will alter the structural and dynamic properties of the COL4A trimer. Further  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 investigations of these families demonstrate a distant relationship, suggesting that the mutations  
5  
6 arose on the same haplotype background indicative of a founder effect.  
7  
8  
9

## 10 11 Case Report

12 This study was approved by the University Health Network Research Ethics Board. The clinical  
13  
14 course of the proband (6442) is characterized by recurrent tonsillitis, hematuria and proteinuria  
15  
16 up to 10 g/day since he was 20 years of age (Figure 1). A renal biopsy was performed revealing  
17  
18 global and segmental glomerulosclerosis with mesangial hypercellularity and glomerular  
19  
20 basement membrane (GBM) thickening by light microscopy (LM) and a homogeneously  
21  
22 thickened GBM with scattered intramembranous densities by electron microscopy (EM) (Figure  
23  
24 1). Immunofluorescent (IF) microscopy showed some linear GBM staining for IgG and IgA and  
25  
26 granular GBM and mesangial staining for IgM (Figure 1). The proband was treated with an ACE  
27  
28 inhibitor and a course of steroids with partial remission of his proteinuria (~2 g/day) at the last  
29  
30 follow-up at age 22.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Interestingly, review of the renal biopsy report from the proband's maternal uncle, 6444,  
42  
43 performed in 1969 at the age of 18 years for proteinuria described similar finding on light  
44  
45 microscopy – GBM thickening with some fuchsinophilic outer capillary wall deposits.  
46  
47

48 Immunofluorescence or electron microscopy was not done. His progressed to end-stage renal  
49  
50 disease (ESRD) by his late 40s.  
51  
52  
53  
54  
55

56 The proband's maternal grandmother, 6465, did not have a significant renal history until she was  
57  
58 diagnosed with high-grade urothelial cancer at age 78. Her father was reported to have passed  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 away from kidney failure in his early 20s, and had a brother also affected by renal disease. Two  
5  
6 male grandchildren of this latter individual developed kidney failure: 6471, was the recipient of a  
7  
8 live donor renal transplant at the age of 25 years from his sister. His brother, 6470, had up to  
9  
10 approximately 800 mg of protein excretion in a 24 hour period and developed ESRD at the age  
11  
12 of 48 years.  
13  
14

15  
16  
17  
18 The proband's mother and aunt, 6443 and 6533, had normal urinalysis in 2013 and 2014,  
19  
20 respectively, in the 4<sup>th</sup> and 5<sup>th</sup> decades of life. Their sisters, 6596 and 6599, were reported to not  
21  
22 have kidney disease. The son to 6596 (7435) was identified to have microscopic hematuria and  
23  
24 proteinuria in his teenage years.  
25  
26  
27  
28  
29  
30

31 The absence of disease in four putative obligate female carriers (i.e. 6443, 6465, 6596, and 6466)  
32  
33 in this family suggested an X-linked recessive inheritance. We performed parametric multipoint  
34  
35 linkage analysis on 7 informative individuals in the pedigree, using genotype data generated with  
36  
37 the Illumina HumanCoreExome-12 v1.0 array. The linkage analysis was conducted under a rare  
38  
39 X-linked recessive model, and demonstrated a 14.35 cM region on the X-chromosome with a  
40  
41 peak LOD score of 1.8, from rs10126713 to rs5911135 (Figure 1). Simulations based on the  
42  
43 same family structure, inheritance model and linkage parameter values suggested that the  
44  
45 maximum attainable X-chromosome LOD score was 1.8.  
46  
47  
48  
49  
50  
51

52  
53 Genotyped individuals clustered with HapMap Caucasian European (CEU) samples.<sup>7</sup> A shared  
54  
55 missense variant within the *COL4A5* gene, c.T665G, p.F222C, within the linked region was  
56  
57 identified in exome sequence data (Figure 1). This mutation was not found in dbSNP138, 1000  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 Genomes Project release version 01-11-2004, Exome Sequencing Project 21-06-2014 or ExAC  
5  
6  
7 01-11-2014.  
8  
9

10  
11 In 2011, a family from the United States (U.S.) was reported as having similar renal  
12  
13 histopathological characteristics.<sup>6</sup> The X-linked recessive inheritance pattern prompted Sanger  
14  
15 sequencing of *COL4A5*, revealing the same variant, c.T665G, p.Phe222Cys.<sup>6</sup> In 2015, a second  
16  
17 family from Germany with affected male cousins was reported to have the same sequence  
18  
19 variant.<sup>5</sup> We genotyped an affected male (6692) from the 2011 report using Illumina  
20  
21 HumanCoreExome-12v1-1A. Relationship checking comparing mitochondrial genotypes  
22  
23 between 6692 and 6442/6470 from our pedigree did not reveal close maternal relatedness.  
24  
25  
26 However, a shared haplotype spanning physical distance of 18.5 Mb (genetic distance of 17.4  
27  
28 cM) between coordinates 97,025,440 (rs5921899) and 115,480,782 (rs11091077) containing  
29  
30 1620 SNPs on the X-chromosome between our proband (6442) and an affected individual from  
31  
32 the U.S. family (6692) was identified.<sup>8-10</sup>  
33  
34  
35  
36  
37  
38  
39  
40

41 We obtained X chromosome exome sequence variant data belonging to the two affected males  
42  
43 (335\_2, 335\_5) from the German family reported in 2015 and compared to sequence data from  
44  
45 the proband belonging to our pedigree (6442).<sup>5</sup> This analysis revealed a shared 14.5 Mb  
46  
47 haplotype around *COL4A5* between coordinates 103,267,865 (rs553509) and 117,718,760  
48  
49 (rs1781090). The shared haplotype amongst the four affected individuals, at least one from each  
50  
51 of the three families (6442, 6692, 335\_2, 335\_5), was chr X: 103, 267, 865 and 115, 480, 782  
52  
53 around *COL4A5*.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 To analyze the possible effect of the p.Phe222Cys substitution, we created a homology model of  
5  
6 part of the  $\alpha3\alpha4\alpha5$  heterotrimer (Figure 2).<sup>11-16</sup> Collagen triple helical regions have a repetitive  
7  
8 sequence with a Gly-Xaa-Yaa motif, Xaa and Yaa being any amino acids, but COL4A5 contains  
9  
10 22 interruptions, which are sites of increased flexibility, and are important for the network  
11  
12 formed in GBM.<sup>2, 15-19</sup> The p.Phe222Cys mutation is located in one of them (GLNFQG). In the  
13  
14 model, Phe222 forms a hydrophobic cluster with the corresponding residues in the other strands,  
15  
16 as previously observed in other interruptions, where these inter-chain interactions stabilize the  
17  
18 triple helix, and can favor the assembly of the trimer in the correct register.<sup>15, 17, 20</sup> Substitution of  
19  
20 Cys would remove this stabilizing interaction, thus changing the structural and dynamical  
21  
22 properties of the trimer. The mutation could also perturb protein-protein interactions (heat shock  
23  
24 protein 47 binds at the mutation site).<sup>2</sup> Alternatively, the introduction of a Cys residue might  
25  
26 cause the formation of an aberrant S-S bridge (for instance with Cys266 in  $\alpha4$ ).<sup>21</sup>  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 Discussion

37  
38 Genetic analysis performed in two affected related males with an unusual X-linked  
39  
40 glomerulopathy, characterized by global and segmental glomerulosclerosis, mesangial expansion  
41  
42 and vague basement membrane immune complex deposition, revealed a rare *COL4A5* mutation,  
43  
44 c.T665G, p.Phe222Cys. Review of the literature identified two families with the same *COL4A5*  
45  
46 variant and showing similar atypical histopathological features, suggesting a unique pathologic  
47  
48 mechanism initiated by this specific mutation. Mitochondrial haplogroups differed and no  
49  
50 evidence for relationship between the pedigrees could be determined using autosome-wide SNP  
51  
52 data. However, analysis of shared variants around the mutation among affected members of the  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 three families indicates a distant relationship and that the mutations arose on the same haplotype  
5  
6 background suggestive of a founder effect.  
7  
8  
9

10  
11 We speculate that the substitution of phenylalanine with cysteine residue within the non-  
12 collagenous interruption of the  $\alpha 5(\text{IV})$  chain may lead to a new epitope that elicits some sort of  
13  
14 an immune response leading to vague intramembranous deposits. Interestingly, the proband in  
15  
16 this series had a partial response to prednisone therapy. Modeling suggests that the substitution  
17  
18 of phenylalanine with cysteine within the repeat interruption of GLY-X-Y will alter the  
19  
20 structural and dynamic properties of the col4a trimer. Out of more than 300 missense variants  
21  
22 reported in the Alport syndrome database  
23  
24 ([http://www.arup.utah.edu/database/alport/ALPORT\\_welcome.php](http://www.arup.utah.edu/database/alport/ALPORT_welcome.php), accessed October 4, 2016),  
25  
26 p.Phe222Cys remains the only pathogenic missense mutation that occurs within a non-  
27  
28 collagenous interruption.<sup>22</sup> It is thus conceivable that the structural and dynamic effects of this  
29  
30 substitution might lead to a different Alport phenotype.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 This report on XLAS with a *COL4A5* p.Phe222Cys variant illustrates the specific influence that  
42  
43 gene mutation can have on phenotype. Homology modeling suggests that the substitution will  
44  
45 change the structural and dynamic properties of the COL4  $\alpha 3\alpha 4\alpha 5$  heterotrimer, though how this  
46  
47 leads to the unusual pathology observed is still unclear. While this is the third report of a family  
48  
49 with this variant, our genetic analysis indicates that affected individuals across the pedigrees are  
50  
51 descendants of a common founder, arguing against a mutational hotspot in the non-collagenous  
52  
53 interruption.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**ACKNOWLEDGEMENTS**

M.B. and D.C. received a Health Research Grant (14-04) from Physician’s Services Incorporated which funded this work. M.B. is supported by a new investigator award from the Kidney Research Scientist Core Education and National Training Program (KRESCENT). M.W. and A.K. were supported by the German Research Foundation (3598/3-1 and CRC 1140). Y.P. was supported by a grant from the Kidney Foundation of Canada. The authors wish to thank the patients and their families for their participation. The authors also wish to thank Sergio Pereira, Daniel Merico, Wilson Sung and Bhooma Thiruvahindrapuram of The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada for assistance with sequencing and variant calling; as well as Winnie Chan for assistance with patient recruitment.

**FINANCIAL DISCLOSURES**

ALS has a consulting agreement with Allena Pharmaceuticals.

## REFERENCES

1. Keithi-Reddy S KR. Molecular and genetic basis of Alport Syndrome. In: Mount H PM, ed. *Molecular and Genetic Basis of Renal Disease*: W.B. Saunders; 2008:151-171.
2. Parkin JD, San Antonio JD, Pedchenko V, Hudson B, Jensen ST, Savige J. Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes. *Human mutation*. 2011;32:127-143.
3. Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. *Journal of the American Society of Nephrology : JASN*. 2001;12:97-106.
4. Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2006;21:665-671.
5. Wuttke M, Seidl M, Malinoc A, et al. A COL4A5 mutation with glomerular disease and signs of chronic thrombotic microangiopathy. *Clin Kidney J*. 2015;8:690-694.
6. Becknell B, Zender GA, Houston R, et al. Novel X-linked glomerulopathy is associated with a COL4A5 missense mutation in a non-collagenous interruption. *Kidney international*. 2011;79:120-127.
7. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS genetics*. 2006;2:e190.
8. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. *Nature genetics*. 2002;30:97-101.
9. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature genetics*. 2011;43:491-498.
10. Ott J. Computer-simulation methods in human linkage analysis. *Proceedings of the National Academy of Sciences of the United States of America*. 1989;86:4175-4178.
11. Biasini M, Bienert S, Waterhouse A, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic acids research*. 2014;42:W252-258.
12. Bella J, Liu J, Kramer R, Brodsky B, Berman HM. Conformational effects of Gly-X-Gly interruptions in the collagen triple helix. *J. Mol. Biol*. 2006;362:298-311.
13. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics*. 2011;27:343-350.
14. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. *Journal of computational chemistry*. 2004;25:1605-1612.
15. Li Y, Brodsky B, Baum J. NMR shows hydrophobic interactions replace glycine packing in the triple helix at a natural break in the (Gly-X-Y)<sub>n</sub> repeat. *J. Biol. Chem*. 2007;282:22699-22706.
16. Zhou J, Hertz JM, Leinonen A, Tryggvason K. Complete amino acid sequence of the human alpha 5 (IV) collagen chain and identification of a single-base mutation in exon 23 converting glycine 521 in the collagenous domain to cysteine in an Alport syndrome patient. *J. Biol. Chem*. 1992;267:12475-12481.
17. Sun X, Chai Y, Wang Q, Liu H, Wang S, Xiao J. A Natural Interruption Displays Higher Global Stability and Local Conformational Flexibility than a Similar Gly Mutation Sequence in Collagen Mimic Peptides. *Biochemistry (Mosc)*. 2015;54:6106-6113.
18. Mohs A, Popiel M, Li Y, Baum J, Brodsky B. Conformational features of a natural break in the type IV collagen Gly-X-Y repeat. *J. Biol. Chem*. 2006;281:17197-17202.
19. Brazel D, Oberbaumer I, Dieringer H, et al. Completion of the amino acid sequence of the alpha 1 chain of human basement membrane collagen (type IV) reveals 21 non-triplet interruptions located within the collagenous domain. *Eur. J. Biochem*. 1987;168:529-536.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

20. Xiao J, Sun X, Madhan B, Brodsky B, Baum J. NMR studies demonstrate a unique AAB composition and chain register for a heterotrimeric type IV collagen model peptide containing a natural interruption site. *J. Biol. Chem.* 2015;290:24201-24209.

21. Renieri A, Bruttini M, Galli L, et al. X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene. *Am J Hum Genet.* 1996;58:1192-1204.

22. Crockett DK, Pont-Kingdon G, Gedge F, Sumner K, Seamons R, Lyon E. The Alport syndrome COL4A5 variant database. *Human mutation.* 2010;31:E1652-1657.

1  
2  
3  
4 **LEGENDS**  
5

6 **Figure 1. Pedigree of X-linked recessive family with unusual glomerulopathy, pathology**

7 **and genetic analysis.** (a) Pedigree. Individuals where DNA was available are represented with a  
8  
9 4 digit number. The proband is indicated with an arrow. Affected individuals are shown in black.  
10  
11 Whole exome sequencing was performed in individuals 6442 and 6444, revealing a shared rare  
12  
13 *COL4A5* variant, c.T665G or p.F222C (NM\_000495, rs281874761). Sanger sequencing of the  
14  
15 *COL4A5* region was done in all individuals where DNA was available. Males hemizygous for  
16  
17 the variant are denoted with an “M” (mutation) while females heterozygous for the variant are  
18  
19 denoted with a “C” (carrier). Individuals where whole genome genotyping was performed for  
20  
21 linkage analysis are indicated with a “+”. (b) Renal biopsy showed thickened glomerular  
22  
23 basement membranes, mesangial expansion by cells and matrix (PAS, 40 x), besides (not shown)  
24  
25 global and segmental glomerulosclerosis; Immunofluorescence showed linear glomerular  
26  
27 capillary wall staining for albumin (2+), IgA (1-2+) and IgG (1+) and segmental granular  
28  
29 mesangial and capillary wall staining for IgM (1-2+), besides (not shown) normal staining for  
30  
31 collagen IV alpha 1, 3 and 5 chains; Electron Microscopy revealed mostly homogeneously  
32  
33 thickened glomerular basement membranes, rare loops with lamellations, and quite a few  
34  
35 scattered intramembranous and partly resorbed subepithelial electron dense deposits (8000 x). (c)  
36  
37 Linkage analysis and exome data. Analysis revealed a region on the X-chromosome from  
38  
39 90,000,000 to 118,700,000 (hg19 build 37) spanning 14.35 cM with a peak LOD score of 1.8  
40  
41 (left). Targeted exome enrichment and massively parallel sequencing was performed on genomic  
42  
43 DNA from two affected individuals, the proband (6442) and his maternal uncle (6444), resulting  
44  
45 in 56,702,602 and 42,709,094 reads, respectively. Following alignment, target region coverage  
46  
47 had an average sequencing depth of 66X and 53X for the two samples. Exome sequencing  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


1  
2  
3  
4 revealed a *COL4A5* variant, c.T665G, p.F222C, shared between the affected related male  
5  
6 individuals as shown in Integrative Genomic Viewer, which was not reported in dbSNP138,  
7  
8  
9 1000 Genomes Project release version 01-11-2004, Exome Sequencing Project 21-06-2014 or  
10  
11 ExAC 01-11-2014.  
12  
13

14 **Figure 2. Homology model of the  $\alpha3\alpha4\alpha5$  heterotrimer in correspondence of the mutation**


15 **site.** A homology model for the collagen 4 triple helix ( $\alpha3$ ,  $\alpha4$  and  $\alpha5$  chains) in the region  
16  
17 surrounding the amino acidic substitution was obtained with the DeepView software and the  
18  
19 SwissModel server, using the crystallographic structure of a trimer with a G1G gap as a template  
20  
21 (PDB code 1Ei8), obtaining a favorable model quality estimate QMEAN Z-score of -0.94.<sup>11-13</sup>  
22  
23 Several possibilities exist for the register between the three chains, which in the collagen trimer  
24  
25 are staggered with respect to each other. The order  $\alpha3\alpha5\alpha4$  (in the trailing, middle, and leading  
26  
27 chain notation) was selected for the model, based on optimization of interactions between the  
28  
29 chains, minimization of the number of steps without Gly residues, and by analogy to the  $\alpha1\alpha1\alpha2$   
30  
31 trimer.<sup>15</sup> Molecular graphics and analyses were realized with the UCSF Chimera software  
32  
33 package.<sup>14</sup> The protein backbone is reported in ribbon representation, with Gly residues colored  
34  
35 in yellow, while all others are shown in red ( $\alpha3$ ), green ( $\alpha4$ ) or blue ( $\alpha5$ ). Interruptions in the  
36  
37 Gly-Xaa-Yaa repetition are colored in lighter colors (pink, cyan, and light green for  $\alpha3$ ,  $\alpha4$  and  
38  
39  $\alpha5$ , respectively. Phe222 (purple) and the hydrophobic residues interacting with it (Val222 and  
40  
41 Ile223 in  $\alpha3$ , Val236 and Val238 in  $\alpha4$  and Leu220 in  $\alpha5$ , shown in grey) are reported in a semi-  
42  
43 transparent space filling representation. Arg221 in in  $\alpha3$ , corresponding to a HSP47 binding site,  
44  
45 is shown in orange, in stick representation.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65




a)




b)



c)







Click here to access/download

**Supplementary file that cannot be built into manuscript  
PDF (eg, movie, dataset)**  
Cover letter Barua.pdf